NEW YORK (GenomeWeb) – MDxHealth today announced a deal with Miraca Life Sciences to promote MDxHealth's ConfirmMDx Prostate Cancer test.
"Through this strategic partnership with MDxHealth, we can now offer a well-validated epigenetic assay, which delivers new molecular insights on a patient's risk for undetected cancer, thereby enabling our clients make more informed decisions about the need for a repeat prostate biopsy," Miraca President and CEO Frank Basile said in a statement.
The firm provides pathology services in dermatology, hematology, gastroenterology, and urology.
ConfirmMDx is an epigenetic assay that helps urologists distinguish patients with true-negative biopsies from those at risk for occult cancer. MDxHealth inked a deal with American Pathology Partners in May to promote and co-market the test in the US.